MedTrace Logo

Perindopril Amlodipine for the Treatment of Hypertension

NCT01556997 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 837

Last updated 2015-09-28

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the safety and efficacy of a fixed-dose combination drug compared to two other drugs (monotherapies) in controlling hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

XOMA 985

PERa/AMLb capsule taken once daily by mouth for six weeks

DRUG

Amlodipine Besylate

AMLb capsule taken once daily by mouth for six weeks

DRUG

Perindopril Erbumine

PERe capsule taken once daily by mouth for six weeks

Sponsors & Collaborators

  • Symplmed Pharmaceuticals LLC

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2013-02-28
Completion
2013-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01556997 on ClinicalTrials.gov